Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Current Medical Research and Opinion|December 20, 2024
Dapagliflozin reduces the white coat effect on systolic blood pressure of patients with type 2 diabetes: a post-hoc analysis from the ADDENDA-BHS 2 trialPamela Nogueira Cavalcante, Joaquim Barreto, Sheila T Kimura-Medorima, et al.
Atherosclerosis|March 11, 2021
Coronavirus disease-19: The multi-level, multi-faceted vasculopathyThiago Quinaglia, Mahsima Shabani, Ikaro Breder, et al.
Atherosclerosis|June 12, 2010
Reduction of endoplasmic reticulum stress--a novel mechanism of action of statins in the protection against atherosclerosisIkaro Breder, Andressa Coope, Ana Paula Arruda, et al.
Atherosclerosis|March 10, 2026
LDL subspecies and lipidome change by evolocumab add-on therapy to empagliflozin in patients with type 2 diabetes: A prespecified secondary analysis of a randomized clinical trialIsabella Bonilha, Marcos Yukio Yoshinaga, Adriano Britto Chaves-Filho, et al.
Nutrition & Diabetes|June 13, 2021
Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitusVaneza Lira W Wolf, Ikaro Breder, Luiz Sérgio F de Carvalho, et al.
Diagnostics (Basel, Switzerland)|April 23, 2022
Compliance with Cardiovascular Prevention Guidelines in Type 2 Diabetes Individuals in a Middle-Income Region: A Cross-Sectional AnalysisJoaquim Barreto, Beatriz Luchiari, Vaneza L W Wolf, et al.
International Journal of Molecular Sciences|April 13, 2024
Effect of Empagliflozin with or without the Addition of Evolocumab on HDL Subspecies in Individuals with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EXCEED-BHS3 TrialIsabella Bonilha, Érica Ivana Lázaro Gomes, Helison R P Carmo, et al.
Therapeutic Advances in Chronic Disease|October 16, 2020
Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trialIkaro Breder, Jessica Cunha Breder, Isabella Bonilha, et al.
Diabetes & Metabolism|September 19, 2021
Dapagliflozin increases retinal thickness in type 2 diabetic patients as compared with glibenclamide: A randomized controlled trialVicente Hidalgo Rodrigues Fernandes, Fernando R P Chaves, Alexandre A S Soares, et al.
Revista Da Associacao Medica Brasileira (1992)|February 14, 2019
Prevalence, treatment, and control of dyslipidemia in diabetic participants of two brazilian cohorts: a place far from heavenNestor S Martins, Daniel S S Mello, Joaquim Barreto, et al.
Pageof 2